News Sentiment

DMAA sentiment intelligence

Drugs Made In America Acquisition Corp. Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 33 relevant articles
Exchange NASDAQ United States
Sector Financial Services Market context
Industry Shell Companies Read-through group
Latest close 10.63 Week of 19 Jun 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

90/100 classification confidence.

Company focus 33

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+0.1% over one week, +0.3% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Drugs Made In America Acquisition Corp (DMAA) Financial Health: Profitability & Balance Sheet Analysis

Market Reaction

Balanced read

53/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 90/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 0.3% over four weeks
Fair value 3.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 1
Neutral 31
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 33
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 15
TradingView 4
MarketBeat 3
Stock Titan 2
Minichart 1
Barchart 1
Investing.com 1
Morningstar 1

Event Lens

What the news is about

Classified themes
Deals and strategy 29
Market update 3
Earnings 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 33
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAA) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Drugs Made In America Acquisition Corp (DMAA), focusing on its profitability and balance sheet. It notes that relevant financial data regarding cash, assets, liabilities, free cash flow, revenue, operating profit, and operation

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 17:41
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp

This article provides an overview of Drugs Made In America Acquisition Corp (DMAA), including its current stock price, market capitalization, and P/E ratio. It notes that relevant revenue breakdown data by business segment and region has not yet been disclosed by the company. The

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 06:39
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAAR) Institutional Confidence

This article provides details on the institutional confidence in Drugs Made In America Acquisition Corp (DMAAR), including its stock price, market cap, and various institutional shareholdings. It lists major institutional investors and their shareholdings, as well as changes in t

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 06:09
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAAU) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Drugs Made In America Acquisition Corp (DMAAU), detailing its current stock price, market cap, and indicating that relevant valuation data like P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. It briefly outlines t

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAAU) Institutional Confidence

This article from TradingKey provides an overview of Drugs Made In America Acquisition Corp (DMAAU) focusing on its institutional confidence. It lists key institutional shareholders and their recent activity, showing both increases and decreases in shares held. The data highlight

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAAU) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Drugs Made In America Acquisition Corp (DMAAU), detailing various risk metrics such as volatility, maximum drawdown, and return-to-drawdown ratios. It presents a quantitative overview of the stock's risk profile based on metrics like be

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAAU) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Drugs Made In America Acquisition Corp (DMAAU), focusing on its profitability and balance sheet. However, the report indicates that relevant financial data for profitability, operational efficiency, growth potential, and shareh

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Drugs Made In America Acquisition Corp (DMAA), including its current market data, P/E ratio, and market capitalization. It highlights that relevant data for financial forecasting, such as EPS, Revenue, and Net Profit, have not yet be

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 01:10
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAA) Institutional Confidence

This article provides details on the institutional confidence in Drugs Made In America Acquisition Corp (DMAA), focusing on changes in institutional shareholding. It lists key shareholders and their recent activity, including increases and decreases in shares held by major invest

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 01:10
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Drugs Made In America Acquisition Corp (DMAA), focusing on its PE, PB, and fair value. It notes that relevant data for these metrics have not yet been disclosed by the company. The company closed at $10.620 with a market cap of $257.8

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 23:10
Source
TradingKey
TradingKey Direct company coverage

Drugs Made In America Acquisition Corp (DMAA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Drugs Made In America Acquisition Corp (DMAA), listing major shareholders and their respective proportions. It also presents institutional shareholding data over several quarters and reports on significant shareholder activities i

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 20:39
Source
TradingKey
TradingView Direct company coverage

Drugs Made In America Acquisition to Merge With Power Analytics Global in Deal Valued Up to $1 Billion

Drugs Made In America Acquisition (DMAA) has entered into a Definitive Merger Agreement with Power Analytics Global (PAGC), an AI and cybersecurity company. The deal values PAGC at up to $1 billion, with a floor valuation of $300 million, and is intended to take PAGC public. Post

Tone
Positive 76/100
Event
Deals and strategy
Published
05 May 2026 23:38
Source
TradingView
Barchart Direct company coverage

DMAAR Price History for Drugs Made IN America Acquisition Corp. Rights Stock

This Barchart.com page provides detailed price history information for Drugs Made IN America Acquisition Corp. Rights (DMAAR) stock. It includes tabs for end-of-day prices, latest trades, and corporate actions, with options for members to download historical data. The page also f

Tone
Neutral 50/100
Event
Deals and strategy
Published
21 Apr 2026 08:09
Source
Barchart
MarketBeat Direct company coverage

Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Up 0.2% - Time to Buy?

Drugs Made In America Acquisition (NASDAQ: DMAA) rose 0.2% to $10.40 during midday trading on Tuesday but traded well below its average daily volume. Analyst sentiment is predominantly negative, with Weiss Ratings reaffirming a "Sell (D-)" rating. Despite this, several institutio

Tone
Negative 39/100
Event
Deals and strategy
Published
14 Jan 2026 07:58
Source
MarketBeat
KLAS 8 News Now Direct company coverage

Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025

Drugs Made In America Acquisition II Corp. announced that, effective December 3, 2025, holders of its units from the initial public offering can trade ordinary shares and rights separately on the Nasdaq Global Market. Each unit comprises one ordinary share and a right to receive

Tone
Neutral 50/100
Event
Deals and strategy
Published
03 Dec 2025 06:34
Source
KLAS 8 News Now
TradingView Direct company coverage

Drugs Made In America Acquisition Corp. SEC 10-Q Report

Drugs Made In America Acquisition Corp. (DMAA) has released its Q3 2025 Form 10-Q report, detailing financial performance and operational progress. The blank check company, focused on the pharmaceutical industry, reported a net income of $2.18 million for the quarter, primarily f

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 Nov 2025 05:37
Source
TradingView
TradingView Direct company coverage

Drugs Made In America Acquisition II Corp. SEC 10-Q Report

Drugs Made In America Acquisition II Corp. (DMIIU), a blank check company, has released its Form 10-Q report for Q3 2025, detailing a net loss of $46,158 for the quarter and $143,558 for the nine months ended September 30, 2025. The company, which completed its IPO in September 2

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 Nov 2025 05:37
Source
TradingView